MétaCan
Menu
Back to cohort

A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCIC CTG IND.154

2005· article· en· W2242358350 on OpenAlexaffabout
K. N., E. Eisenhauer, Lillian L. Siu, Holger W. Hirte, Sebastién J. Hotte, Stephen Chia, Jennifer J. Knox, Emma S. Tomlinson Guns, Jean Powers, Martin Gleave

Bibliographic record

VenueJournal of Clinical Oncology · 2005
Typearticle
Languageen
FieldMedicine
TopicClusterin in disease pathology
Canadian institutionsBC Cancer Agency
Fundersnot available
KeywordsClusterinDocetaxelMedicineToxicityInternal medicinePeripheral blood mononuclear cellPhases of clinical researchOncologyChemotherapyApoptosisBiology

Abstract

fetched live from OpenAlex

3085 Background: The clusterin gene encodes a cytoprotective chaperone protein that promotes cell survival, is expressed in a variety of cancers, and increases in response to apoptotic stimuli. OGX-011 (OGX, Oncogenex Technologies Inc) is a 2’methoxyethyl antisense complimentary to clusterin mRNA that inhibits expression with a tissue t1/2 >7 days in pre-clinical studies. A phase I trial of OGX in men prior to prostatectomy identified biologically active doses of 480 and 640mg as determined by clusterin suppression effects. The objective of this phase I study was to define a phase II dose of OGX in combination with docetaxel. Methods: The study was conducted at 3 centers in Canada. Patients (pts) with cancers known from the literature to express clusterin were eligible. OGX was given by 2 hr IV infusion at fixed doses starting at 40mg weekly after loading on days 1, 3, and 5. Docetaxel was given IV 30 mg/m2/week (w) for 5 out of 6w or 75 mg/m2 every 3w. Serial samples of peripheral blood mononuclear cells and serum were assessed for clusterin as were accessible malignant tissues. Results: 26 pts (9 prostate, 8 ovary, 3 NSCLC, 4 renal, 1 breast and other) have been enrolled to 6 cohorts with doses of OGX up to 640mg delivered with weekly docetaxel. 24 pts are evaluable for toxicity. Toxicity was typical for docetaxel with 3 pts having grade 3 treatment related toxicity (allergic, gastrointestinal, fatigue). OGX attributable adverse events were grade 1/2, including fevers, rigors, fatigue and transient AST and ALT elevations. OGX AUC and CMAX increased linearly with dose with no apparent effect on docetaxel pharmacokinetics. Serial baseline serum clusterin levels were consistent, but by treatment day 8 decreased in 3/3 pts by a mean of 52% (SD=26%) at the 640 mg dose level. Of 18 pts with measurable disease, there has been 1 partial response and 5 patients with stable disease. Conclusions: OGX can be given at biologically active doses with standard doses of weekly docetaxel. Accrual continues and additional cohorts are evaluating OGX with docetaxel q3w. Phase II trials of this combination are planned in pts with breast and prostate cancer. Supported by a grant from the NCIC and a grant in aid from Aventis Pharma. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration OncoGeneX Technologies OncoGeneX Technologies

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.422
Threshold uncertainty score0.585

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0030.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0020.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.137
GPT teacher head0.490
Teacher spread0.352 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations15
Published2005
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicClusterin in disease pathologyFrench-language works237,207